Tocqueville Asset Management L.P. Aerie Pharmaceuticals Inc Transaction History

Tocqueville Asset Management L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 08, 2019	SELL	$33.0 - $60.04 $2.67 Million - $4.86 Million	-80,920 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$56.15 - $73.9 $182,206 - $239,805	-3,245 Reduced 3.86%	80,920 $4.98 Million
Q2 2018 Aug 13, 2018	BUY	$47.85 - $70.45 $864,171 - $1.27 Million	18,060 Added 27.32%	84,165 $5.69 Million
Q1 2018 May 14, 2018	SELL	$51.15 - $61.0 $4.17 Million - $4.97 Million	-81,465 Reduced 55.2%	66,105 $3.59 Million
Q4 2017 Feb 13, 2018	BUY	$50.85 - $65.1 $1.99 Million - $2.55 Million	39,120 Added 36.07%	147,570 $8.82 Million
Q3 2017 Oct 30, 2017	BUY	$48.6 - $60.1 $5.27 Million - $6.52 Million	108,450	108,450 $5.27 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on Tocqueville Asset Management L.P. with notifications on news.